As Precision Medicine and Genomics move to the center of global drug development, the complexity of managing distributed R&D increases exponentially. India offers significant advantages in NGS throughput and bioinformatics, yet global innovators face systemic risks in data fidelity, clinical relevance, and regulatory bridging.
Aventiq Bio serves as your Independent Technical Proxy in India. We provide high-level governance for NGS platforms, biomarkers, and Companion Diagnostics (CDx), ensuring that genomics-driven programs are built on audit-ready data and defensible partner intelligence.
We perform no sequencing or bioinformatics. Our neutrality ensures unbiased partner vetting and objective data audits.
Specialized governance for patient stratification, oncology biomarkers, and CDx-linked assets.
Advisory frameworks designed to bridge Indian NGS operations and FDA/EMA/CLIA standards.
Conflict-free advisory (we perform no sequencing or bioinformatics). Precision-oncology focus. Regulatory-convergence frameworks that bridge Indian operations to FDA/EMA/CLIA standards. ALCOA+ data standards and ironclad IP firewalls.
Press Enter to search